tiprankstipranks
Trending News
More News >
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
US Market

PROCEPT BioRobotics (PRCT) Stock Forecast & Price Target

Compare
635 Followers
See the Price Targets and Ratings of:

PRCT Analyst Ratings

Strong Buy
10Ratings
Strong Buy
8 Buy
2 Hold
0 Sell
Based on 10 analysts giving stock ratings to
PROCEPT
BioRobotics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRCT Stock 12 Month Forecast

Average Price Target

$51.75
▲(58.16% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for PROCEPT BioRobotics in the last 3 months. The average price target is $51.75 with a high forecast of $65.00 and a low forecast of $38.00. The average price target represents a 58.16% change from the last price of $32.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","46":"$46","63":"$63","80":"$80","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,46,63,80,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.41,33.07076923076923,35.73153846153846,38.392307692307696,41.05307692307692,43.713846153846156,46.37461538461538,49.035384615384615,51.69615384615385,54.35692307692308,57.017692307692315,59.67846153846154,62.33923076923077,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.41,32.05153846153846,33.69307692307692,35.33461538461538,36.97615384615385,38.61769230769231,40.25923076923077,41.90076923076923,43.542307692307695,45.183846153846154,46.82538461538462,48.46692307692308,50.10846153846154,{"y":51.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.41,30.993846153846153,31.577692307692306,32.16153846153846,32.745384615384616,33.32923076923077,33.91307692307692,34.496923076923075,35.08076923076923,35.66461538461539,36.24846153846154,36.832307692307694,37.41615384615385,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":96.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$65.00Average Price Target$51.75Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on PRCT
Truist Financial
Truist Financial
$50$47
Buy
43.64%
Upside
Reiterated
12/18/25
Procept BioRobotics price target lowered to $47 from $50 at TruistProcept BioRobotics price target lowered to $47 from $50 at Truist
UBS
$62
Buy
89.49%
Upside
Initiated
12/12/25
Promising Growth and Investment Opportunity for PROCEPT BioRobotics: Analyst Buy Rating
Bank of America Securities Analyst forecast on PRCT
Bank of America Securities
Bank of America Securities
$55$38
Hold
16.14%
Upside
Downgraded
12/08/25
Procept BioRobotics downgraded to Neutral from Buy at BofAProcept BioRobotics downgraded to Neutral from Buy at BofA
Piper Sandler Analyst forecast on PRCT
Piper Sandler
Piper Sandler
$50
Buy
52.81%
Upside
Reiterated
12/08/25
Analysts Offer Insights on Healthcare Companies: Cooper Co (NASDAQ: COO), PROCEPT BioRobotics (NASDAQ: PRCT) and Crispr Therapeutics AG (NASDAQ: CRSP)
Morgan Stanley Analyst forecast on PRCT
Morgan Stanley
Morgan Stanley
$56$51
Buy
55.87%
Upside
Reiterated
12/02/25
Procept BioRobotics price target lowered to $51 from $56 at Morgan StanleyProcept BioRobotics price target lowered to $51 from $56 at Morgan Stanley
TD Cowen
$85$50
Buy
52.81%
Upside
Reiterated
11/05/25
Josh Jennings Reaffirms Buy Rating on PROCEPT BioRobotics Amid Strong Q3 Results and Conservative 2026 Forecast
William Blair Analyst forecast on PRCT
William Blair
William Blair
Buy
Reiterated
11/05/25
Buy Rating Affirmed Amid Temporary Setbacks and Strategic Growth Prospects
Wells Fargo Analyst forecast on PRCT
Wells Fargo
Wells Fargo
$58$51
Buy
55.87%
Upside
Reiterated
11/05/25
Procept BioRobotics price target lowered to $51 from $58 at Wells FargoProcept BioRobotics price target lowered to $51 from $58 at Wells Fargo
BTIG
Hold
Reiterated
11/05/25
PROCEPT BioRobotics: Hold Rating Amid Strong Revenue but Concerns Over Utilization and Sales Cycles
Leerink Partners Analyst forecast on PRCT
Leerink Partners
Leerink Partners
$83$65
Buy
98.66%
Upside
Reiterated
10/14/25
PROCEPT BioRobotics (PRCT) Gets a Buy from Leerink Partners
Oppenheimer Analyst forecast on PRCT
Oppenheimer
Oppenheimer
$60
Buy
83.37%
Upside
Upgraded
09/02/25
Procept BioRobotics upgraded to Outperform from Perform at OppenheimerProcept BioRobotics upgraded to Outperform from Perform at Oppenheimer
Stephens
$70
Buy
113.94%
Upside
Initiated
07/09/25
Procept BioRobotics initiated with an Overweight at StephensProcept BioRobotics initiated with an Overweight at Stephens
Jefferies
Hold
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on PRCT
Truist Financial
Truist Financial
$50$47
Buy
43.64%
Upside
Reiterated
12/18/25
Procept BioRobotics price target lowered to $47 from $50 at TruistProcept BioRobotics price target lowered to $47 from $50 at Truist
UBS
$62
Buy
89.49%
Upside
Initiated
12/12/25
Promising Growth and Investment Opportunity for PROCEPT BioRobotics: Analyst Buy Rating
Bank of America Securities Analyst forecast on PRCT
Bank of America Securities
Bank of America Securities
$55$38
Hold
16.14%
Upside
Downgraded
12/08/25
Procept BioRobotics downgraded to Neutral from Buy at BofAProcept BioRobotics downgraded to Neutral from Buy at BofA
Piper Sandler Analyst forecast on PRCT
Piper Sandler
Piper Sandler
$50
Buy
52.81%
Upside
Reiterated
12/08/25
Analysts Offer Insights on Healthcare Companies: Cooper Co (NASDAQ: COO), PROCEPT BioRobotics (NASDAQ: PRCT) and Crispr Therapeutics AG (NASDAQ: CRSP)
Morgan Stanley Analyst forecast on PRCT
Morgan Stanley
Morgan Stanley
$56$51
Buy
55.87%
Upside
Reiterated
12/02/25
Procept BioRobotics price target lowered to $51 from $56 at Morgan StanleyProcept BioRobotics price target lowered to $51 from $56 at Morgan Stanley
TD Cowen
$85$50
Buy
52.81%
Upside
Reiterated
11/05/25
Josh Jennings Reaffirms Buy Rating on PROCEPT BioRobotics Amid Strong Q3 Results and Conservative 2026 Forecast
William Blair Analyst forecast on PRCT
William Blair
William Blair
Buy
Reiterated
11/05/25
Buy Rating Affirmed Amid Temporary Setbacks and Strategic Growth Prospects
Wells Fargo Analyst forecast on PRCT
Wells Fargo
Wells Fargo
$58$51
Buy
55.87%
Upside
Reiterated
11/05/25
Procept BioRobotics price target lowered to $51 from $58 at Wells FargoProcept BioRobotics price target lowered to $51 from $58 at Wells Fargo
BTIG
Hold
Reiterated
11/05/25
PROCEPT BioRobotics: Hold Rating Amid Strong Revenue but Concerns Over Utilization and Sales Cycles
Leerink Partners Analyst forecast on PRCT
Leerink Partners
Leerink Partners
$83$65
Buy
98.66%
Upside
Reiterated
10/14/25
PROCEPT BioRobotics (PRCT) Gets a Buy from Leerink Partners
Oppenheimer Analyst forecast on PRCT
Oppenheimer
Oppenheimer
$60
Buy
83.37%
Upside
Upgraded
09/02/25
Procept BioRobotics upgraded to Outperform from Perform at OppenheimerProcept BioRobotics upgraded to Outperform from Perform at Oppenheimer
Stephens
$70
Buy
113.94%
Upside
Initiated
07/09/25
Procept BioRobotics initiated with an Overweight at StephensProcept BioRobotics initiated with an Overweight at Stephens
Jefferies
Hold
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PROCEPT BioRobotics

1 Month
xxx
Success Rate
10/13 ratings generated profit
77%
Average Return
+11.58%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +11.58% per trade.
3 Months
xxx
Success Rate
12/18 ratings generated profit
67%
Average Return
+6.18%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.18% per trade.
1 Year
Richard NewitterTruist Financial
Success Rate
13/27 ratings generated profit
48%
Average Return
+20.13%
reiterated a buy rating 7 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 48.15% of your transactions generating a profit, with an average return of +20.13% per trade.
2 Years
xxx
Success Rate
11/27 ratings generated profit
41%
Average Return
+0.94%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.74% of your transactions generating a profit, with an average return of +0.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRCT Analyst Recommendation Trends

Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
5
6
6
8
9
Buy
19
15
6
4
6
Hold
18
16
9
8
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
37
21
20
22
In the current month, PRCT has received 15 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. PRCT average Analyst price target in the past 3 months is 51.75.
Each month's total comprises the sum of three months' worth of ratings.

PRCT Financial Forecast

PRCT Earnings Forecast

Next quarter’s earnings estimate for PRCT is -$0.32 with a range of -$0.35 to -$0.28. The previous quarter’s EPS was -$0.38. PRCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRCT is -$0.32 with a range of -$0.35 to -$0.28. The previous quarter’s EPS was -$0.38. PRCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.

PRCT Sales Forecast

Next quarter’s sales forecast for PRCT is $93.74M with a range of $92.80M to $94.11M. The previous quarter’s sales results were $83.33M. PRCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.
Next quarter’s sales forecast for PRCT is $93.74M with a range of $92.80M to $94.11M. The previous quarter’s sales results were $83.33M. PRCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.

PRCT Stock Forecast FAQ

What is PRCT’s average 12-month price target, according to analysts?
Based on analyst ratings, PROCEPT BioRobotics’s 12-month average price target is 51.75.
    What is PRCT’s upside potential, based on the analysts’ average price target?
    PROCEPT BioRobotics has 58.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRCT a Buy, Sell or Hold?
          PROCEPT BioRobotics has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
            What is PROCEPT BioRobotics’s price target?
            The average price target for PROCEPT BioRobotics is 51.75. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $65.00 ,the lowest forecast is $38.00. The average price target represents 58.16% Increase from the current price of $32.72.
              What do analysts say about PROCEPT BioRobotics?
              PROCEPT BioRobotics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of PRCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.